{"id":"NCT01358864","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","officialTitle":"A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2013-02","completion":"2014-05","firstPosted":"2011-05-24","resultsPosted":"2015-10-28","lastUpdate":"2016-08-29"},"enrollment":678,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"BI 201335","otherNames":[]},{"type":"DRUG","name":"Pegylated Interferon-alpha (IFN)","otherNames":[]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo/PegIFN/RBV","type":"ACTIVE_COMPARATOR"},{"label":"BI201335 12 weeks","type":"EXPERIMENTAL"},{"label":"BI201335 24 weeks","type":"EXPERIMENTAL"}],"summary":"The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 48 weeks as compared to PegIFN/RBV alone in chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN/RBV treatment.","primaryOutcome":{"measure":"Sustained Virological Response 12 Weeks Post Treatment (SVR12)","timeFrame":"12 weeks post treatment, up to 60 weeks","effectByArm":[{"arm":"Relapser & Partial: Placebo","deltaMin":10.3,"sd":null},{"arm":"Relapser & Partial: Faldaprevir 12 Weeks","deltaMin":65.4,"sd":null},{"arm":"Relapser & Partial: Faldaprevir 24 Weeks","deltaMin":61.4,"sd":null},{"arm":"Null:Faldaprevir 12 Weeks","deltaMin":33.8,"sd":null},{"arm":"Null:Faldaprevir 24 Weeks","deltaMin":32.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":null},{"comp":"OG003 vs OG004","p":null},{"comp":"OG003","p":"<0.0001"},{"comp":"OG004","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":116,"countries":["United States","Austria","Belgium","Canada","France","Germany","Japan","Portugal","Puerto Rico","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":78},"commonTop":["Nausea","Pruritus","Fatigue","Headache","Diarrhoea"]}}